About Us
Provascor is a privately held company developing new therapeutics for heart and vascular diseases. It has an experienced team of scientists, drug development specialists, operating management team with drug development experience, cardiologists, heart failure specialists, clinical pharmacologists, and regulatory experts. It has developed two small molecule drugs that treat late stage heart failure and acute ischemic stroke, respectively. Intellectual property protection includes novel intravenous, subcutaneous, oral formulations, unique methods of use and key manufacturing steps. The development team works closely with the board of directors and its equity investors. Our team is dedicated to improving heart and vascular health that enhance lives.
Our Team
Provascor's Assets
The company has two new small molecule chemical entities. One is a novel therapeutic agent for patients with heart failure using a platform of formulations to treat the full spectrum of patients ranging from advanced heart failure to those with less severe heart failure. The drug candidate has a heart-specific protective mechanism. It is in clinical stage of development having completed A Phase 1a trial without any safety concern and demonstrates a 16-fold therapeutic range. The companies second drug candidate has unique anti-inflammatory properties showing strong efficacy in animals with ischemic stroke. The drug candidate is in late stage preclinical development.
Contact Information
Corporate Office
261 Saint Ronan Street, New Haven, CT 06511, USA
Other Information:
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital, Family Wealth Fund, Non-dilutive Grants
Primary Industry
Drug Discovery and Development
Other Industries
Biotechnology and Cardiovascular Therapeutics
Vertical(s)
Frequently Asked Questions
Please reach us at if you cannot find an answer to your question.
Provascor is a privately held company developing disruptive technologies to treat patients with heart and vascular diseases. It has novel drug candidates to transform the way we treat these patients.
The heart failure drug candidate is in clinical stage. The stroke drug candidate has preclinical proof of concept and is in late preclinical stage of development.
Provascor has raised pre-seed and seed funds. It is currently raising investment capital to move the stroke technology to a clinical stage and the heart failure asset to the next clinical trial.
This website uses cookies.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.